Ista Pharmaceuticals Inc.

The Irvine developer of products to treat eye diseases said it lost $5.2 million, or 33 cents a share, for the first quarter, compared with a pro forma net loss of $4.6 million a year earlier. No revenue was recorded for the company, which went public in August.